FR2919305B1 - Vecteurs viraux adeno-associes pour l'expression de la dysferline. - Google Patents

Vecteurs viraux adeno-associes pour l'expression de la dysferline.

Info

Publication number
FR2919305B1
FR2919305B1 FR0705479A FR0705479A FR2919305B1 FR 2919305 B1 FR2919305 B1 FR 2919305B1 FR 0705479 A FR0705479 A FR 0705479A FR 0705479 A FR0705479 A FR 0705479A FR 2919305 B1 FR2919305 B1 FR 2919305B1
Authority
FR
France
Prior art keywords
dysferline
adeno
expression
viral vectors
associated viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0705479A
Other languages
English (en)
Other versions
FR2919305A1 (fr
Inventor
Isabelle Richard
Marc Bartoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENETHON ASS LOI DE 1901
Original Assignee
GENETHON ASS LOI DE 1901
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENETHON ASS LOI DE 1901 filed Critical GENETHON ASS LOI DE 1901
Priority to FR0705479A priority Critical patent/FR2919305B1/fr
Priority to PCT/FR2008/051414 priority patent/WO2009016326A2/fr
Priority to EP08826741A priority patent/EP2173765A2/fr
Priority to CA2697127A priority patent/CA2697127A1/fr
Priority to US12/670,451 priority patent/US20100266551A1/en
Publication of FR2919305A1 publication Critical patent/FR2919305A1/fr
Application granted granted Critical
Publication of FR2919305B1 publication Critical patent/FR2919305B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0705479A 2007-07-26 2007-07-26 Vecteurs viraux adeno-associes pour l'expression de la dysferline. Expired - Fee Related FR2919305B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0705479A FR2919305B1 (fr) 2007-07-26 2007-07-26 Vecteurs viraux adeno-associes pour l'expression de la dysferline.
PCT/FR2008/051414 WO2009016326A2 (fr) 2007-07-26 2008-07-25 Vecteurs viraux adéno-associés pour l'expression de la dysferline
EP08826741A EP2173765A2 (fr) 2007-07-26 2008-07-25 Vecteurs viraux adéno-associés pour l'expression de la dysferline
CA2697127A CA2697127A1 (fr) 2007-07-26 2008-07-25 Vecteurs viraux adeno-associes pour l'expression de la dysferline
US12/670,451 US20100266551A1 (en) 2007-07-26 2008-07-25 Adeno-associated viral vectors for the expression of dysferlin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0705479A FR2919305B1 (fr) 2007-07-26 2007-07-26 Vecteurs viraux adeno-associes pour l'expression de la dysferline.

Publications (2)

Publication Number Publication Date
FR2919305A1 FR2919305A1 (fr) 2009-01-30
FR2919305B1 true FR2919305B1 (fr) 2009-09-18

Family

ID=39113936

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0705479A Expired - Fee Related FR2919305B1 (fr) 2007-07-26 2007-07-26 Vecteurs viraux adeno-associes pour l'expression de la dysferline.

Country Status (5)

Country Link
US (1) US20100266551A1 (fr)
EP (1) EP2173765A2 (fr)
CA (1) CA2697127A1 (fr)
FR (1) FR2919305B1 (fr)
WO (1) WO2009016326A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075008A1 (fr) 2011-11-16 2013-05-23 University Of Florida Research Foundation Inc. Systèmes de vecteur double aav pour une thérapie génique
RU2527073C2 (ru) * 2012-12-24 2014-08-27 Общество с ограниченной ответственностью "НекстГен" Кодон-оптимизированная кднк, кодирующая дисферлин человека, генно-инженерная конструкция, рекомбинантный аденовирус и фармацевтическая композиция для лечения дисферлинопатий
WO2015187825A2 (fr) 2014-06-03 2015-12-10 University Of Massachusetts Compositions et méthodes de modulation de l'expression de la dysferline
JP6889717B2 (ja) 2015-11-12 2021-06-18 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 筋ジストロフィーの治療方法
AU2017285423A1 (en) * 2016-06-17 2019-01-03 Texas Tech University System Truncated dysferlin for treatment of dysferlinopathy
US11660353B2 (en) 2018-04-27 2023-05-30 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
US20210246443A1 (en) * 2018-06-08 2021-08-12 University Of Massachusetts Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011157A1 (fr) * 1998-08-25 2000-03-02 The General Hospital Corporation Dysferline, gene mute dans la myopathie distale et la myopathie des ceintures
US20020076754A1 (en) * 2000-04-20 2002-06-20 Liangwu Sun Overcoming AAV vector size limitation through viral DNA hetero-dimerization

Also Published As

Publication number Publication date
WO2009016326A2 (fr) 2009-02-05
FR2919305A1 (fr) 2009-01-30
WO2009016326A3 (fr) 2009-04-30
EP2173765A2 (fr) 2010-04-14
US20100266551A1 (en) 2010-10-21
CA2697127A1 (fr) 2009-02-05

Similar Documents

Publication Publication Date Title
BRPI0810646A2 (pt) " compostos farmacêuticos ".
BRPI0916123A2 (pt) "composição de xampu concentrada"
BRPI0819014A2 (pt) "descanso de braço"
ITMI20080342A1 (it) Macchina modulare atta ad eseguire l'assemblaggio di due tessuti mediante adesivazione con o senza nastratura.
BRPI0808246A2 (pt) "fralda descartável".
BRPI0914503A2 (pt) "composição de shampoo concentrado"
FR2919305B1 (fr) Vecteurs viraux adeno-associes pour l'expression de la dysferline.
BRPI0916180A2 (pt) "sapato com um membro elástico no fundo"
BRPI0922645A2 (pt) "arilamidas tiadiazol substituídas".
FR2939766B1 (fr) Pylone central d'aeronef.
BRPI0817136A2 (pt) "aba de fixação"
FR2891181B1 (fr) Dispositf pour la fente de buches
ITVE20070098A1 (it) "procedimento, particolarmente per la realizzazione di calzature antistatiche"
FR2889177B1 (fr) Materiau de coeur pour tubulure.
FR2923694B1 (fr) Accessoire pour l'utilisation de sachets de preparation de boissons
GB0724282D0 (en) The 'opbric' system
FR2917963B3 (fr) Ensemble prothetique pour l'articulation de l'epaule.
ITMO20070046A1 (it) "apparato per l' essicazione di materiali, particolarmente zeoliti o simili"
FR2926023B1 (fr) Utilisation d'une homoproteine de la famille bicoid pour le traitement du glaucome.
AT505229A3 (de) Potenzhilfe ''penisschlauch''
FR2913183B1 (fr) Dispositif pour l'absorption de la transpiration
FR2946534B1 (fr) Utilisation d'alkylglycerols pour la preparation de medicaments.
FR2938438B1 (fr) Composition pour l'elimination de la plaquette d'atherome
ITMI20062515A1 (it) Procedimento per la preparazione di 3,6-di-o-aceti-d-glicali
FR2898291B3 (fr) Normographe pour le rasage.

Legal Events

Date Code Title Description
TQ Partial transmission of property
ST Notification of lapse

Effective date: 20140331